Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same class has impressed in a recent phase 2 clinical trial – and it only needs to be taken once a month.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes,